Breaking News Instant updates and real-time market news.

PM

Philip Morris

$98.88

-1.45 (-1.45%)

, CVS

CVS Health

$74.35

0.33 (0.45%)

20:25
02/07/18
02/07
20:25
02/07/18
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Philip Morris (PM), consensus $1.35... CVS Health (CVS), consensus $1.89... Regeneron Pharmaceuticals (REGN), consensus $4.53... Thomson Reuters (TRI), consensus 58c... Tyson Foods (TSN), consensus $1.50... Yum! Brands (YUM), consensus 80c... Alexion Pharmaceuticals (ALXN), consensus $1.28... Kellogg (K), consensus 96c... Cardinal Health (CAH), consensus $1.15... Twitter (TWTR), consensus 14c... KKR (KKR), consensus 52c... Masco (MAS), consensus 44c... Coty (COTY), consensus 23c... Nielsen (NLSN), consensus 80c... BorgWarner (BWA), consensus $1.01... Goodyear Tire (GT), consensus 76c... Sealed Air (SEE), consensus 57c... Hanesbrands (HBI), consensus 52c... GrubHub (GRUB), consensus 31c... Sally Beauty (SBH), consensus 42c.

PM

Philip Morris

$98.88

-1.45 (-1.45%)

CVS

CVS Health

$74.35

0.33 (0.45%)

REGN

Regeneron

$334.61

-4.19 (-1.24%)

TRI

Thomson Reuters; also use TRIN

$40.56

-0.01 (-0.02%)

TSN

Tyson Foods

$73.38

-0.81 (-1.09%)

YUM

Yum! Brands

$80.13

-0.45 (-0.56%)

ALXN

Alexion

$117.15

2.24 (1.95%)

K

Kellogg

$64.21

-0.95 (-1.46%)

CAH

Cardinal Health

$65.14

-0.3 (-0.46%)

TWTR

Twitter

$26.91

1.67 (6.62%)

KKR

KKR

$22.19

0.12 (0.54%)

MAS

Masco

$42.69

0.35 (0.83%)

COTY

Coty

$17.48

0.05 (0.29%)

NLSN

Nielsen

$37.56

0.7 (1.90%)

BWA

BorgWarner

$55.00

0.84 (1.55%)

GT

Goodyear Tire

$33.47

0.09 (0.27%)

SEE

Sealed Air

$44.36

0.08 (0.18%)

HBI

Hanesbrands

$21.96

0.33 (1.53%)

GRUB

GrubHub

$69.91

1.01 (1.47%)

SBH

Sally Beauty

$15.69

0.27 (1.75%)

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 12

    Feb

  • 12

    Feb

  • 16

    Feb

  • 19

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 05

    Mar

  • 07

    Mar

  • 30

    May

PM Philip Morris
$98.88

-1.45 (-1.45%)

01/19/18
01/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Outperform from Neutral at Wedbush analyst Christopher Svezia saying the brand's new footwear styles are "notably higher" versus a year ago while comparisons are easing, particularly around key categories like basketball. 2. Abercrombie & Fitch (ANF) upgraded to Buy from Hold at Argus with analyst John Eade saying the stock has "fallen out of favor" with its core market, but the turnaround strategy implemented by the new CEO, along with the hiring of a Chief Marketing Officer, has produced two consecutive quarter of earnings beats. 3. Chipotle (CMG) upgraded to Market Perform from Underperform at Raymond James with analyst Brian Vaccaro citing fair valuation and no longer sees downside risk given management's decision to take a third and final round of menu price increases and stabilizing industry demand trends. 4. Foot Locker (FL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Kelly Chen saying the worst of the athletic industry's issues have passed. 5. Philip Morris (PM) and Altria Group (MO) were upgraded to Buy from Hold at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/26/18
MSCO
01/26/18
NO CHANGE
MSCO
FDA comments suggest no imminent MRTP approval for iQOS, says Morgan Stanley
Morgan Stanley analyst Matthew Grainger said the FDA panels votes yesterday highlighted that the committee is "directionally accepting" of iQOS' harm reduction potential, but does not yet feel there is sufficient evidence to support a formal claim that Philip Morris' "heat not burn" tobacco device carries lower health risks or would be beneficial to population health. The CTP Director's commentary at the end of the meeting reinforced that the FDA will maintain an ongoing dialogue about Philip Morris' Modified Risk Tobacco Product, or MRTP, application, but Grainger expects this to occur over a longer time frame, he tells investors. The analyst still sees the FDA issuing a PMTA authorization within the next 12-18 months, but sees the MRTP process extending "well beyond" May 2018, he added.
01/26/18
JEFF
01/26/18
NO CHANGE
JEFF
Buy
Jefferies sees 'big opportunity' in British American Tobacco after selloff
Jefferies analyst Owen Bennett sees a "big opportunity" in shares of British American Tobacco (BTI) following yesterday's selloff. There is a "very strange disconnect here," Bennett tells investors in a research note. The 3.5% pullback doesn't make sense, he adds. He believes that if the market thinks Philip Morris' (PM) IQOS won't get approved, then it is a positive for British American Tobacco. The analyst thinks the selloff can only be explained by holders assuming a Premarket Tobacco Application for IQOS will be approved. Such an approval will likely create support for Philip Morris and Altria Group (MO), Bennett argues. Following conversations in the U.S., the analyst sees a "complete lack of knowledge" around where British American Tobacco stands with heated tobacco approvals. Bennett has Buy ratings on all three stocks.
01/19/18
JEFF
01/19/18
UPGRADE
Target $124
JEFF
Buy
Philip Morris upgraded to Buy from Hold at Jefferies
Jefferies analyst Owen Bennett upgraded Philip Morris to Buy saying he's bullish on Tobacco for fiscal 2018. The analyst sees returns driven by "solid" EBITDA, easing regulatory concerns and benefits from tax reform. He also sees the possibility of large-scale acquisitions adding to the upside. The analyst upped his price target for Philip Morris shares to $124. Bennett this morning also upgraded Altria Group (MO) to Buy. British American Tobacco (BTI) remains his top pick, followed by Altria, then Philip Morris.
CVS CVS Health
$74.35

0.33 (0.45%)

02/01/18
02/01/18
DOWNGRADE
Target $69

Underperform
Express Scripts downgraded to Underperform at Bernstein
As previously reported, Bernstein analyst Lance Wilkes downgraded Express Scripts to Underperform from Market Perform, with a $69 price target, as he believes tax reform is fully price in and his original concerns on the standalone PBM model remain. Further, the analyst sees additional risks from a potential CVS (CVS)/Aetna (AET) merger and Amazon (AMZN) threats.
01/31/18
RBCM
01/31/18
UPGRADE
Target $98
RBCM
Outperform
Express Scripts upgraded to Outperform at RBC Capital
As reported earlier, RBC Capital analyst George Hill upgraded Express Scripts (ESRX) to Outperform and raised his price target to $98 from $68. Hill cites the "recent sharp pullback on Amazon's (AMZN) healthcare entry" de-risking the stock, while also pointing to the trend of vertical integration as seen in the CVS (CVS)-Aetna (AET) deal. The analyst believes Express Scripts could also become an attractive M&A target as "one of the few remaining assets at scale".
01/31/18
PIPR
01/31/18
NO CHANGE
Target $212
PIPR
Overweight
Piper sees buying opportunity in Aetna after yesterday's pullback
Piper Jaffray analyst Sarah James sees a buying opportunity in Aetna (AET) following yesterday's 3% pullback on the Amazon (AMZN), Berkshire (BRK.A) and JPMorgan (JPM) news. The company yesterday morning posted a solid earnings beat driven by strong cost trend management in the government and commercial businesses, James tells investors in a research note. She raised her price target for Aetna shares to $212 from $207 and keeps an Overweight rating on the name. CVS Health's (CVS) takeout offer now values the shares at $212, up from $207 previously, based on 0.8378 shares of CVS stock plus $145 per share in cash, James points out. The analyst sees a "win-win" setup for the stock based on the deal going through or the company remaining standalone.
01/31/18
SBSH
01/31/18
DOWNGRADE
Target $212
SBSH
Neutral
Aetna downgraded to Neutral from Buy at Citi
Citi analyst Ralph Giacobbe downgraded Aetna (AET) to Neutral while raising his price target for the shares to $212 from $197. The analyst feels a Neutral rating is more appropriate with the spread to the CVS Health (CVS) takeover bid narrowing.
REGN Regeneron
$334.61

-4.19 (-1.24%)

12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
12/29/17
PIPR
12/29/17
NO CHANGE
PIPR
Biotech fund outflows continue, says Piper Jaffray
For the weekly period ending Wednesday, December 27, healthcare/biotech funds saw $338M in net outflows, representing a 0.58% decrease in assets, Piper Jaffray analyst Christopher Raymond tells investors in a research note. This marks the seventh straight negative week and the eleventh week of outflows in the past 12 weeks, the analyst points out in a research note titled "Ending 2017 on a Down Note: Biotech Outflows Continue."
01/09/18
SBSH
01/09/18
NO CHANGE
Target $388
SBSH
Neutral
Regeneron to save big from tax reform, says Citi
Citi analyst Robyn Karnauskas raised her price target for Neutral-rated Regeneron Pharmaceuticals to $388 from $380 saying the company will save big from tax reform. Regeneron noted that it will benefit from tax reform and guided for a 2018 effective tax rate of 15%-19% versus the consensus at 28%, Karnauskas tells investors in a research note. She notes that the company plans to reinvest much of the savings.
TRI Thomson Reuters; also use TRIN
$40.56

-0.01 (-0.02%)

01/31/18
MSCO
01/31/18
NO CHANGE
Target $40
MSCO
Overweight
Blackstone could be next disruptor, says Morgan Stanley
Following Blackstone's (BX) purchase of a 55% stake in Thomson Reuters' Financial and Risk business, Morgan Stanley analyst Michael Cyprys said Blackstone's deal signals the growing value in data and he sees opportunities for the asset manager to enhance its tool kit with big data and AI in order to bring transformational change to companies and industries. With nearly $100B in dry powder on which leverage can be applied, suggesting well over half trillion in spending power, Cyprys sees potential for Blackstone to act as a disruptor, he tells investors. The analyst keeps an Overweight rating and $40 price target on Blackstone shares.
01/31/18
EDJN
01/31/18
DOWNGRADE
EDJN
Hold
Thomson Reuters downgraded to Hold from Buy at Edward Jones
01/31/18
NATB
01/31/18
DOWNGRADE
NATB
Sector Perform
Thomson Reuters downgraded to Sector Perform from Outperform at National Bank
01/31/18
DADA
01/31/18
NO CHANGE
Target $174
DADA
Neutral
Thomson Reuters-Blackstone F&R talks are negative for FactSet, says DA Davidson at DA Davidson
DA Davidson analyst Peter Heckmann says that yesterday's disclosure of advanced talks between Blackstone (BX) and Thomson Reuters (TRI) about the sale of the latter's Financial & Risk - F&R - operations is a negative for Factset (FDS). The analyst believes that most of the market share wins for Factset have come from Reuters over the past two decades, and Blackstone's ability to better focus investments in the financial data business may make competitive wins for difficult. Heckmann keeps his Neutral rating and $174 price target, adding "FactSet's shares will be challenged to outperform the peer group over the next year".
TSN Tyson Foods
$73.38

-0.81 (-1.09%)

11/15/17
11/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tyson Foods (TSN) upgraded to Buy from Hold at Argus with analyst John Staszak saying the company's wide range of food business offerings gives it an edge over less diversified competitors, adding that growing demand for meat products will result in better than expected operating income over the next two years. 2. Sangamo (SGMO) upgraded to Overweight from Neutral at Piper Jaffray with analyst Charles Duncan saying he sees a "reinvigorated" company with a reestablished clinical stage pipeline. 3. Alaska Air (ALK) upgraded to Strong Buy from Outperform at Raymond James with analyst Savanthi Syth saying risk/reward is compelling following the recent pullback. 4. Ingredion (INGR) upgraded to Overweight from Equal Weight at Stephens with analyst Farha Aslam saying she views the company being well positioned to deliver double-digit EPS growth given an improving product mix, recovery in South America, and cash flow that can be deployed for dealmaking or share repurchases. 5. Tesaro (TSRO) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez citing more favorable risk/reward, particularly for longer term shareholders, and recent weakness in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/18
SPHN
01/29/18
NO CHANGE
Target $65
SPHN
Overweight
Conagra,Tyson could be Pinnacle buyers if Third Point pushes sale, says Stephens
Stephens analyst Farha Aslam noted that reports indicated that Dan Loeb's Third Point has taken a position in Pinnacle Foods (PF) and she believes an activist campaign would likely focus on a sale rather than management or operational changes. The analyst, who estimates Pinnacle could be valued at $67-$70 in an acquisition, views Conagra Brands (CAG) and Tyson Foods (TSN) as potential acquirers, noting that Pinnacle has been considered an acquisition target since Hillshire was bought by Tyson in 2014. Aslam keeps an Overweight rating and $65 price target on Pinnacle shares.
01/04/18
PIPR
01/04/18
INITIATION
Target $94
PIPR
Overweight
Tyson Foods initiated with an Overweight at Piper Jaffray
Piper Jaffray started Tyson Foods with an Overweight rating and $94 price target.
01/04/18
PIPR
01/04/18
INITIATION
Target $94
PIPR
Overweight
Piper sees multiple expansion for Tyson, starts at Overweight
Piper Jaffray analyst Brett Wong started Tyson Foods with an Overweight rating and $94 price target. The analyst sees the valuation multiple expanding as the company goes through its strategic transformation to focus on growing more value-added products. He also believes tax reform will drive earnings upside.
YUM Yum! Brands
$80.13

-0.45 (-0.56%)

01/30/18
NOMU
01/30/18
DOWNGRADE
Target $89
NOMU
Neutral
Yum! Brands downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Mark Kalinowski downgraded Yum! Brands to Neutral with an unchanged price target of $89. The analyst cites valuation and concerns a possible 2018 slowdown in U.S. same-store-sales for the downgrade.
01/30/18
01/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Underperform from Market Perform by analyst Alex Arfaei, who said the risk/reward has "meaningfully changed" after the rise in the stock price, adding that the new focus on fundamentals beyond the benefits of tax reform suggests "significant price erosion in immunology driven by interchangeable biosimilar anti-TNFs, and lower effectiveness of the 'Rebate Trap' to block access to cheap biosimilars". 2. iRobot (IRBT) downgraded to Neutral from Buy at Sidoti by analyst Frank Camma, who cited valuation as shares approach his $98 price target. 3. Horizon Global (HZN) downgraded to Market Perform from Outperform at BMO Capital by analyst Gerrick Johnson, who said that while he still sees "strong demand in key end markets," operation execution, rising input costs, and high debt levels are concerning. The analyst added that the company may have "lost the faith of investors" after a 30% drop in the stock price following the guidance cut. 4. Yum! Brands (YUM) downgraded to Neutral from Buy at Nomura Instinet by analyst Mark Kalinowshi, who cited valuation and concerns a possible 2018 slowdown in U.S. same-store-sales. 5. Alaska Air (ALK) downgraded to Underweight from Neutral at JPMorgan by analyst Jamie Baker, who noted that the airline is the only name where he had to cut his 2019 estimates. He also believes the company "remains in the United crosshairs in San Francisco." The analyst also downgraded Southwest (LUV) to Neutral from Overweight, and said he believes better relative value exists elsewhere in the Airlines sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/26/18
EDJN
01/26/18
UPGRADE
EDJN
Buy
Yum! Brands upgraded to Buy from Hold at Edward Jones
01/02/18
WELS
01/02/18
NO CHANGE
WELS
Potbelly, Del Taco may see largest EPS tailwind from tax reform, says Wells Fargo
Wells Fargo argues that Potbelly (PBPB), Del Taco (TACO), El Pollo Loco (LOCO) and Jack in the Box (JACK) could see the largest EPS accretion tailwind from a reduced corporate tax rate, with Restaurant Brands (QSR), Red Robin (RRGB), Noodles & Company (NDLS) and Yum! Brands (YUM) the companies that could see the smallest tailwind. Recent restaurant rally indicates that virtually the entire sector has benefited from anticipation of potential tax reform, with the most heavily shorted names seeing an amplified move, the firm adds.
ALXN Alexion
$117.15

2.24 (1.95%)

02/05/18
EVER
02/05/18
UPGRADE
EVER
Outperform
Alexion upgraded to Outperform from In Line at Evercore ISI
01/04/18
01/04/18
DOWNGRADE
Target $130

Outperform
Alexion downgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James downgraded Alexion to Outperform from Strong Buy and lowered its price target to $130 from $178. Analyst Laura Chico believes risk/reward is more limited at current levels, particular when tax reform is a headwind for the company.
02/02/18
DBAB
02/02/18
NO CHANGE
Target $163
DBAB
Buy
Deutsche Bank remains bullish on Alexion ahead of data
The upcoming read-outs from two ongoing Phase 3 trials in paroxysmal nocturnal hemoglobinuria comparing ALXN1210 versus Soliris will be critical to the success of Alexion shares both in the near and long-term, Deutsche Bank analyst Andrew Peters tells investors in a research note. The analyst remains bullish on the stock into the read-outs saying the data suggest a highly effective clinical profile. He keeps a Buy rating on Alexion with a $163 price target.
01/18/18
FBCO
01/18/18
INITIATION
Target $147
FBCO
Outperform
Alexion assumed with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster assumed coverage of Alexion Pharmaceuticals with an Outperform rating and $147 price target. The analyst views the stock as well positioned for 2018 given his expectations that Solaris will gain momentum in generalized myasthenia gravis.
K Kellogg
$64.21

-0.95 (-1.46%)

01/16/18
SBSH
01/16/18
NO CHANGE
Target $91
SBSH
Buy
Kellogg added to U.S. Focus List at Citi
Citi analyst David Driscoll added Kellogg (K) to his firm's U.S. Focus List and raised his price target for the shares to $91 from $86. The analyst sees a good setup for food stocks in 2018 due to improving fundamentals as well as benefits from cost savings and tax reform. He keeps a Buy rating on Kellogg. Driscoll this morning also upgraded Campbell Soup (CPB) to Buy.
02/05/18
PIVT
02/05/18
INITIATION
Target $80
PIVT
Buy
Kellogg initiated with a Buy at Pivotal Research
Pivotal Research analyst Timothy Ramey started Kellogg with a Buy rating and $80 price target, as he argues the risk/reward is compelling ahead of CEO Steve Cahillane discussing his strategy and the company giving its FY18 guidance and detailing the impact of tax code changes within about the next two weeks.
02/05/18
02/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kellogg (K) initiated with a Buy at Pivotal Research. 2. MBIA (MBI) initiated with a Market Perform at Keefe Bruyette. 3. AxoGen (AXGN) initiated with an Outperform at William Blair. 4. Ctrip (CTRP) initiated with a Hold at Deutsche Bank. 5. Sun Hydraulics (SNHY) was initiated with a Buy at SunTrust and an Overweight at KeyBanc. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/17
11/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Kellogg (K) upgraded to Buy from Hold at Argus with analyst David Coleman saying that despite the challenging operating environment, the company will benefit from diminishing currency headwinds and new product launches in the coming quarters. 2. Dominion (D) upgraded to Buy from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith citing improved prospects for a tax reform resolution at VEPCO and expectations for improved execution. 3. Pan American Silver (PAAS) upgraded to Outperform from Neutral at Credit Suisse with analyst Robert Reynolds saying the 4% pullback in shares since the third quarter results provides an attractive valuation and entry point. 4. New Jersey Resources (NJR) upgraded to Buy from Neutral at Janney Capital. 5. Terreno Realty (TRNO) upgraded to Buy from Neutral at National Securities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CAH Cardinal Health
$65.14

-0.3 (-0.46%)

01/04/18
EVER
01/04/18
INITIATION
Target $67
EVER
In Line
Cardinal Health initiated with an In Line at Evercore ISI
Evercore ISI started Cardinal Health with an In Line rating and $67 price target.
11/30/17
JEFF
11/30/17
NO CHANGE
JEFF
Jefferies sees drugstore sentiment improving with no Amazon news
Investors were anticipating an announcement from Amazon.com (AMZN) regarding a pharmacy strategy around Thanksgiving due to recent media reports and the resulting sell-side speculation, Jefferies analyst Brian Tanquilut tells investors in a research note. With no Amazon pharmacy entry announced one week removed from the holiday, the analyst believes investor sentiment over the drug supply chain may gradually improve, at least in the near-term. He notes that the price-to-earnings multiples of Walgreens Boots Alliance (WBA) and CVS Health (CVS) have already declined amid speculation of an Amazon entry. Tanquilut acknowledges, however, that the Amazon overhang will not completely go away. The analyst has Buy ratings on UnitedHealth (UNH) and Walgreens, and Hold ratings on AmerisourceBergen (ABC), Cardinal Health (CAH), CVS and McKesson (MCK).
12/04/17
DBAB
12/04/17
INITIATION
Target $64
DBAB
Hold
Cardinal Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Glen Santangelo started Cardinal Health with a Hold rating and $64 price target. The analyst believes uncertainty around drug pricing and the potential for integration risk with Cordis and the Patient Recovery acquisitions warrant a "more prudent approach" to the shares.
12/04/17
LEER
12/04/17
NO CHANGE
LEER
Amazon entry into healthcare markets focused on medical supplies, says Leerink
Leerink analyst David Larsen says that his recent research around Amazon's (AMZN) licensing activity has shown that the company's entry into healthcare markets is, at least for now, focused on medical supplies and devices rather than pharmaceuticals. The analyst believes Owens & Minor (OMI), Cardinal Health (CAH) and Henry Schein (HSIC) are most exposed but that it will take several years for Amazon Business to scale up manufacturer supply relationships to take significant share. Although the top and bottom line impact may be small over the next year or two, Larsen remains cautious on the group as multiples continue to reflect the Amazon threat as well as pricing and volume headwinds.
TWTR Twitter
$26.91

1.67 (6.62%)

01/23/18
STFL
01/23/18
NO CHANGE
Target $21
STFL
Hold
Fair to question Twitter ad business recovery after Noto loss, says Stifel
Stifel analyst John Egbert said that Anthony Noto was arguably Twitter's most outspoken advocate and was likely involved in negotiating larger advertising commitments. Given his prominent role, it is fair to question whether an advertising business recovery seems less likely now that Noto is departing, argues Egbert, who keeps a Hold rating and $21 price target on Twitter shares.
01/28/18
PIPR
01/28/18
NO CHANGE
PIPR
Growth of sports rights may be coming down, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says he is starting to see some evidence that the growth of sports rights may be coming down toward a more reasonable rate. The analyst notes that only CBS (CBS), Fox (FOXA) and NBC (CMCSK; CMCSA) submitted bids for Thursday Night Football rights, with CBS and NBC submitting bids below their current rate of $450M per year, and Fox making a higher bid for the rights, in a likely effort to establish itself as a "live sports and news" network in the wake of selling a majority of assets to Disney (DIS). On the digital side, Facebook (FB) declined to make an offer for digital streaming rights to TNF, while Amazon (AMZN), which paid $50M this year, and Twitter (TWTR), which paid $10M last year did submit bids.
02/07/18
DBAB
02/07/18
NO CHANGE
Target $22
DBAB
Hold
Twitter price target raised to $22 from $18 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Twitter to $22 saying he believes the company continues to make progress with its turnaround on both user growth and ad revenue. The analyst notes continued improvement in feedback from ad buyers and improving trends in comScore data. Twitter has re-engaged lapsed users, attracted new ones, and now "carries better resonance in the advertising community with better pricing and a more narrow message," Walmsley tells investors in a research note. The analyst, however, remains on the sidelines with a Hold rating on the stock, citing Twitter shares' premium valuation "despite slower growth."
01/23/18
JPMS
01/23/18
NO CHANGE
JPMS
Overweight
Noto departure 'clear negative' for Twitter, says JPMorgan
JPMorgan analyst Doug Anmuth says the departure of Chief Operating Officer Anthony Noto is a "clear negative" for Twitter. Noto has been a "stabilizing force," bringing increased discipline and setting the company up to return to growth in 2018, Anmuth tells investors in a research note. While the analyst is surprised by the timing of the deal, he believes Noto's exit is not "thesis-changing." He continues to believe Twitter's financial results will strengthen over the next year. Anmuth reiterates an Overweight rating on Twitter amid today's selloff.
KKR KKR
$22.19

0.12 (0.54%)

01/30/18
MSCO
01/30/18
NO CHANGE
MSCO
Morgan Stanley says Ares may be first, Apollo may gain most from C-corp convert
Morgan Stanley analyst Michael Cyprys said he sees an opportunity for Alternative Asset Managers to unlock value by converting to C-corps, as shifting from a partnership structure could help alleviate some tax reporting complexities and expand the universe of eligible investors. He sees Ares Management (ARES) as possibly the first to convert and expects a potential announcement or indications of management's intentions about a conversion when the company reports earnings on February 15. While Ares may be first, Cyprys sees Apollo Global (APO) as potentially being able to unlock the most value from a conversion, with 26% near-term upside possible if the shares re-rate. He sees a less favorable conversion scenario for asset managers with lower taxes and/or greater exposure to performance fees, including KKR (KKR), Carlyle Group (CG) and Blackstone (BX), Cyprys tells investors.
01/10/18
FBCO
01/10/18
NO CHANGE
Target $31
FBCO
Outperform
KKR price target raised to $31 from $23 at Credit Suisse
Credit Suisse analyst Craig Siegenthaler raised his price target for KKR to $31 from $23 as he believes the macro backdrop should provide tailwinds for the Alternative Asset Managers while lower corporate tax rate should boost the valuation of their underlying portfolios. The analyst reiterates an Outperform rating on the shares.
01/09/18
GSCO
01/09/18
UPGRADE
Target $29
GSCO
Conviction Buy
KKR upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Alexander Blostein upgraded KKR to Conviction Buy and raised his price target for the shares to $29 from $24.50. The analyst sees the "evolution of KKR's business mix" leading to a more stable earnings profile and higher multiple over time. KKR remains the most inexpensive stock among alternative managers, Blostein tells investors in a research note.
11/28/17
SDLR
11/28/17
INITIATION
Target $21
SDLR
Hold
KKR resumed with a Hold at Sandler ONeill
Sandler O'Neill resumed coverage of KKR with a Hold rating and $21 price target.
MAS Masco
$42.69

0.35 (0.83%)

01/22/18
FBCO
01/22/18
NO CHANGE
Target $46
FBCO
Neutral
Masco price target raised to $46 from $36 at Credit Suisse
Credit Suisse analyst Susan Maklari raised her price target for Masco to $46 from $36 on valuation. The analyst reiterates a Neutral rating on the shares.
12/05/17
WELS
12/05/17
NO CHANGE
WELS
Potential tax reform beneficial Building Products names, says Wells Fargo
Wells Fargo notes that the potential tax reform is "overwhelmingly beneficial" for its Building Products companies under coverage, though certain companies will benefit more than others. On average, the proposed tax reform could increase 2019 EPS by 18%, improve 2019 ROE by about 375 bps and lower 2019 PE multiples by 15%, it contends. Wells Fargo says that the most favorably impacted companies will likely be the Distributors like GMS Inc.(GMS) and Beacon Roofing (BECN), as well as Fortune Brands (FBHS) and Masco (MAS).
01/05/18
JPMS
01/05/18
DOWNGRADE
Target $48
JPMS
Neutral
Masco downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Rehaut downgraded Masco to Neutral with an unchanged price target of $48. The company's turnaround story and benefit from corporate tax reform has largely been reflected by the stock's outperformance in 2017, the analyst tells investors in a research note. He believes further margin improvement in Cabinets and Windows is already reflected by the Street's estimates.
01/03/18
EVER
01/03/18
DOWNGRADE
EVER
In Line
Masco downgraded to In Line from Outperform at Evercore ISI
COTY Coty
$17.48

0.05 (0.29%)

12/12/17
SBSH
12/12/17
UPGRADE
Target $21
SBSH
Buy
Coty upgraded to Buy from Neutral at Citi
Citi analyst Wendy Nicholson upgraded Coty to Buy and raised her price target for the shares to $21 from $17. The analyst sees credibility in the management team improving as core sales growth accelerates and margins expand. She sees the shorts covering their positions as CoverGirl relaunches and points out that skepticism on the stock is high.
11/20/17
DADA
11/20/17
NO CHANGE
Target $2
DADA
Buy
Coty may consider acquiring Avon Products, says DA Davidson
DA Davidson analyst Linda Bolton Weiser speculates that Coty (COTY) may be interested in acquiring Avon Products (AVP). Weiser says Coty has recently added $587M in debt and when asked about it on the earnings call, it claimed it was related to Burberry license acquisition where the payment was only expected to be about $162M. Coty management has also hinted that it intends to grow its EPS by using its balance sheet, says the analyst in her research note. Weiser keeps her Buy rating and $2 price target on Avon, saying the company "represents one of very few ways to gain immediate entry to the Latin American beauty market" while also noting that Coty "raves" about direct-to-consumer sales models.
12/21/17
RBCM
12/21/17
UPGRADE
RBCM
Outperform
Coty upgraded to Outperform from Sector Perform at RBC Capital
12/21/17
12/21/17
UPGRADE
Target $23

Outperform
Coty upgraded to Outperform at RBC Capital
As previously reported, RBC Capital analyst Nik Modi upgraded Coty to Outperform from Sector Perform, stating that his discussions with contacts and meeting with new management have made him more constructive on the company and its opportunity to improve its top line and expand margins. He raised his price target on Coty shares to $23 from $18.
NLSN Nielsen
$37.56

0.7 (1.90%)

01/08/18
BARD
01/08/18
UPGRADE
Target $41
BARD
Outperform
Nielsen upgraded to Outperform at Baird
As previously reported, Baird analyst Jeffrey Meuler upgraded Nielsen to Outperform from Neutral citing its depressed valuation and expectations for improved investors sentiment over time. The analyst sees signs of stabilization in its Buy-Developed Markets, sustained solid growth in Watch, and increased investor confidence in margin expansion. Meuler reiterated his $41 price target on Nielsen shares.
01/08/18
BARD
01/08/18
UPGRADE
BARD
Outperform
Nielsen upgraded to Outperform from Neutral at Baird
01/02/18
MACQ
01/02/18
DOWNGRADE
MACQ
Neutral
Nielsen downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Tim Nollen downgraded Nielsen to Neutral and lowered its price target to $38 from $44 due to deflationary pressures on the underlying business in both media and CPG/retail sectors and lack of catalysts.
12/14/17
12/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Verizon (VZ) downgraded to Hold on valuation at HSBC with analyst Sunil Rajgopal saying the recent rally limits upside. 2. Blue Buffalo Pet Products (BUFF) downgraded to Hold from Buy at Deutsche Bank with analyst Faiza Alwy citing valuation concerns as the stock is up 35% over the last six months. 3. Nielsen (NLSN) downgraded to Underweight from Equal Weight at Barclays with analyst Manav Patnaik saying he sees challenging end markets for the company as well as credibility concerns following a year of "poor" execution. 4. Valeant (VRX) downgraded to Underweight from Neutral at JPMorgan with analyst Chris Schott saying he sees better opportunities in the sector following the recent rally in the shares. 5. Pier 1 Imports (PIR) downgraded to Sell from Hold at Gordon Haskett with analyst Chuck Grom citing the third quarter miss and lowered guidance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BWA BorgWarner
$55.00

0.84 (1.55%)

10/13/17
KEYB
10/13/17
NO CHANGE
Target $106
KEYB
Overweight
Auto suppliers supported by stronger Euro and rising EU output, says KeyBanc
KeyBanc analyst Brett Hoselton raised his profit targets on several auto suppliers, maintaining a positive view on the group overall heading into Q3 earnings. Hoselton says the outlook for the quarter is intact, as lower than expected production of light vehicles was in part offset by stronger EU output. He also cites FX tailwinds, with the Euro have appreciated about 7% sequentially and further supporting revenue in Q3 and possibly FY18. Hoselton raised his profit targets on Delphi Automotive (DLPH) to $106 from $100, Magna International (MGA) to $59 from $55, Lear Corp (LEA) to $184 from $180, and BorgWarner (BWA) to $56 from $50, maintaining an Overweight rating on all these stocks. The analyst is especially bullish on Dana Inc (DNA) given the recent upward revisions to North America Class 8 production, but says his Sector Weight rating reflects the stock prices.
12/05/17
MSCO
12/05/17
NO CHANGE
MSCO
Morgan Stanley raises price targets for American Axle, BorgWarner and Magna
After his recent work made him more cautious on the pace of electric vehicle adoption and penetration, Morgan Stanley analyst Adam Jonas said his negative thesis on American Axle (AXL), BorgWarner (BWA) and Magna (MGA) related to their exposure to internal combustion powered autos has been delayed. Jonas raised his price target for American Axle to $16 from $11 and his target on BorgWarner to $38 from $32, but he maintains Underweight ratings on both. He also raised his price target for Magna to $49 from $47, but keeps an Equal Weight rating on its shares.
12/06/17
OPCO
12/06/17
INITIATION
Target $63
OPCO
Outperform
BorgWarner initiated with an Outperform at Oppenheimer
Oppenheimer started BorgWarner with an Outperform rating and $63 price target.
12/28/17
MSCO
12/28/17
NO CHANGE
MSCO
January to be busy for Autos and Shared Mobility names, says Morgan Stanley
Morgan Stanley analyst Adam Jonas previewed the January calendar for the Autos and Shared Mobility sector, noting that the Vegas CES takes place in the second week and the Detroit Auto Show occurs in the third week of next month. Judging from last year's shows and press releases in recent weeks, he expects "the vast majority" of prepared presentations will focus on autonomous driving, electric propulsion and new business models as companies seek to encourage recognition and valuation of "Auto 2.0 efforts" in the multiples of their stocks, he tells investors. Automakers covered by the firm include Fiat Chrysler (FCAU), Tesla (TSLA), General Motors (GM), Ferrari (RACE) and Ford (F). Auto suppliers covered include Magna (MGA), Goodyear Tire (GT), Adient (ADNT), Delphi Technologies (DLPH), Visteon (VC), BorgWarner (BWA), Aptiv (APTV) and Tenneco (TEN).
GT Goodyear Tire
$33.47

0.09 (0.27%)

01/31/18
LBOW
01/31/18
INITIATION
LBOW
Neutral
Goodyear Tire initiated with a Neutral at Longbow
Longbow analyst Anthony Deem initiated Goodyear Tire with a Neutral reflecting risks to consensus segment operating income estimates. Deem sees 5-10% downside to consensus expectations driven by weaker than expected volume and price/mix and notes valuation is at a multi-year high and reflects "inflated optimism."
11/01/17
11/01/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Motors (GM) downgraded to Neutral from Buy at Nomura Instinet with analyst Anindya Das citing "limited scope" for raising his estimates much higher given the competitive landscape in the North American market. 2. Under Armour (UAA, UA) was downgraded to Hold from Buy at SunTrust and to Sell from Hold at Canaccord. 3. Alaska Air (ALK) and JetBlue (JBLU) were downgraded to Neutral from Overweight at JPMorgan, while United Continental (UAL) and Spirit Airlines (SAVE) were downgraded to Underweight from Neutral. 4. Check Point (CHKP) was downgraded to Equal Weight from Overweight at Stephens, to Neutral from Buy at BTIG, and to Market Perform from Outperform at Cowen. 5. Goodyear Tire (GT) downgraded to Neutral from Buy at Guggenheim with analyst Emmanuel Rosner saying he sees additional downside at current levels due to concerns "deep share losses and margin erosion" could continue given the increasingly competitive tire market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/18
01/31/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lumentum (LITE) was initiated with a Buy at UBS while Oclaro (OCLR) was initiated with a Sell. 2. ImmunoGen (IMGN) initiated with a Buy at H.C. Wainwright. 3. Salesforce (CRM) and Workday (WDAY) were initiated with a Buy at Cleveland Research. 4. Cooper Tire (CTB) was initiated with a Buy at Longbow, while Goodyear Tire (GT) was initiated with a Neutral. 5. Acacia Communications (ACIA) initiated with a Buy at UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SEE Sealed Air
$44.36

0.08 (0.18%)

12/05/17
GABE
12/05/17
NO CHANGE
Target $61
GABE
Buy
Sealed Air named a Best Idea for 2018 at Gabelli
Gabelli analyst Rosemarie Morbelli named Sealed Air Best Idea for 2018. Following the Diversey transaction, Morbelli said Sealed Air's focus is on debt reduction and buybacks, with free cash flow being used to fun internal growth, small tuck-in properties, and adding technologies and or expansion. The analyst rates Sealed Air a Buy with a $61 PMV.
01/31/18
RHCO
01/31/18
DOWNGRADE
Target $48
RHCO
Hold
Sealed Air downgraded to Hold from Buy at SunTrust
SunTrust analyst Jason Freuchtel downgraded Sealed Air to Hold from Buy and lowered his price target to $48 from $49. Freuchtel notes that the stock has performed well since Q3 on positive volume momentum and expectations of capital deployment, but more upside is now limited in the near term while the synergies from acquisitions will take some time to materialize.
12/20/17
VERT
12/20/17
DOWNGRADE
VERT
Hold
Sealed Air downgraded to Hold from Buy at Vertical Research
12/15/17
LEHM
12/15/17
UPGRADE
Target $53
LEHM
Overweight
Sealed Air upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Scott Gaffner upgraded Sealed Air (SEE) to Overweight and raised his price target for the shares to $53 from $46. The company has "self help margin improvement potential" that doesn't rely on industry fundamentals improving, Gaffner tells investors in a research note. The analyst calls Avery Dennison (AVY) his top pick in U.S. Paper & Packaging.
HBI Hanesbrands
$21.96

0.33 (1.53%)

01/19/18
DADA
01/19/18
NO CHANGE
Target $47
DADA
Buy
Columbia Sportswear to benefit from easy SSS and cold weather, says DA Davidson
DA Davidson analyst Andrew Burns previews Q4 earnings for Apparel & Footwear, suggesting that consensus estimates may be attainable and possibly beatable. The analyst notes that last year's underperformance sets up easy comps, while better than expected holiday season and cold winter weather will allow companies to exceed expectations. Burns prefers Columbia Sportswear (COLM) and Hanesbrands (HBI) in the space, keeping a Buy rating on both companies.
12/19/17
12/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Neutral from Buy at Nomura Instinet with analyst Jeffrey Kvaal saying the stock's gains for the iPhone X "supercycle are in the late innings." 2. Hanesbrands (HBI) downgraded to Neutral from Buy at Citi with analyst Kate McShane saying the U.S. wholesale environment remains challenging due to declining traffic trends in stores and price-based competition in all channels. 3. PPL Corp. (PPL) downgraded to Underperform from Neutral at Macquarie with analyst Angie Storozynski saying she thinks the next UK regulatory review will result in a meaningful drop in revenues and believes the high dividend debate will come back into focus. 4. Chubb (CB) downgraded to Neutral from Outperform at Credit Suisse with analyst Ryan Tunis noting that while the integration of ACE Limited (ACE)/Chubb has been successful and positions the latter well for the future, the analyst argues that it is difficult for him to solve for much upside to medium term earnings per share and shares with the integration coming to a close in the fourth quarter. 5. KB Home (KBH) downgraded to Underweight from Neutral at JPMorgan with analyst Michael Rehaut citing valuation with the shares up 100% in 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/17
SBSH
12/19/17
DOWNGRADE
Target $23
SBSH
Neutral
Hanesbrands downgraded to Neutral from Buy at Citi
Citi analyst Kate McShane downgraded Hanesbrands to Neutral saying the U.S. wholesale environment remains challenging due to declining traffic trends in stores and price-based competition in all channels. The analyst does not believe Hanesbrands can fully recoup the loss of sales in-store via online channels. As such, she's less bullish on the company's 2018 prospects and cut her price target for the shares to $23 from $29.
10/25/17
10/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Motors (GM) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Adam Jonas citing the stock's 40% rise over the past year, which he attributes to investors having "finally noticed" the company's "bold and difficult moves" to reposition the core business. 2. Discover (DFS) downgraded to Neutral from Buy at Compass Point with analyst William Ryan citing valuation and lack of catalysts to push shares higher. 3. Hanesbrands (HBI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying the shares have "both longer and shorter-term headwinds to fight through." 4. Chipotle (CMG) downgraded to Market Perform from Outperform at Telsey Advisory with analyst Bob Derrington saying he finds it increasingly difficult to recommend shares given the substantial volatility in its operating results and lack of visibility surrounding its earnings outlook. 5. Acadia (ACHC) was downgraded to Hold from Buy at Deutsche Bank and to Neutral from Outperform at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GRUB GrubHub
$69.91

1.01 (1.47%)

02/05/18
RAJA
02/05/18
DOWNGRADE
RAJA
Market Perform
GrubHub downgraded to Market Perform from Outperform at Raymond James
02/05/18
02/05/18
DOWNGRADE

Market Perform
GrubHub downgraded to Market Perform at Raymond James
As previously reported, Raymond James downgraded GrubHub to Market Perform from Outperform. Analyst Aaron Kessler said GrubHub said risk/reward is less favorable at current levels, consensus estimates appear too high, and UberEats appears to be gaining share in the U.S. online takeout market.
02/05/18
ROTH
02/05/18
NO CHANGE
Target $78
ROTH
Buy
GrubHub price target raised to $78 from $65 at Roth Capital
Roth Capital analyst Darren Aftahi raised his price target for GrubHub to $78 from $65 as he expects it to perform well relative to his Q4 estimates when it reports earnings. However, the analyst believes reduced taxes could yield increased marketing investment and perhaps a higher topline outlook for 2018. He reiterates a Buy rating on the shares.
02/06/18
STFL
02/06/18
NO CHANGE
Target $75
STFL
Buy
GrubHub price target raised to $75 on tax benefits at Stifel
Ahead of GrubHub's upcoming earnings report, Stifel analyst John Egbert raised his 2018 and 2019 EPS forecasts by about 24% and 16%, respectively, to account for his expectation for the company to be one of the larger beneficiaries of recent tax legislation. The analyst, who expects investors to be focused on Grubhub's integration of Eat24 and trends in the company's organic business, raised his price target on the stock to $75 from $63 and keeps a Buy rating on GrubHub shares.
SBH Sally Beauty
$15.69

0.27 (1.75%)

11/16/17
BMOC
11/16/17
NO CHANGE
Target $16
BMOC
Market Perform
Sally Beauty price target lowered to $16 from $21 at BMO Capital
BMO Capital analyst Shannon Coyne lowered the price target on Sally Beauty to $16 following Q4 revenue miss, saying the quarter was in part impacted by the hurricane activity. While the management's commitment to update the company's technology and CRM capabilities is encouraging, writes the analyst, execution risk looms for FY18 amid ongoing challenges of improving traffic trends. The analyst keeps Market Perform rating on Sally Beauty.
11/16/17
DADA
11/16/17
DOWNGRADE
DADA
Neutral
Sally Beauty downgraded to Neutral from Buy at DA Davidson
11/16/17
DADA
11/16/17
DOWNGRADE
Target $16
DADA
Neutral
Sally Beauty downgraded to Neutral at DA Davidson on lower SSS growth
As reported earlier, DA Davidson analyst Linda Bolton Weiser downgraded Sally Beauty to Neutral from Buy and lowered her price target to $16 from $21. Weiser cites below consensus SSS in terms of both reported Q4 and FY18 outlook, adding that declines in EBITDA may also weigh on the company's share buybacks at some point. The analyst also adjusts her model to forecast long term comps at flat to down from flat to up.
11/16/17
COWN
11/16/17
NO CHANGE
Target $18
COWN
Outperform
Sally Beauty price target lowered to $18 from $24 at Cowen
Cowen analyst Oliver Chen lowered his price target on Sally Beauty to $18 from $24 following the company's earnings report, citing execution issues and the impact of the hurricanes. The analyst expects the company to refocus on execution and to accelerate its e-commerce investment to help drive accessibility to brands and capture incremental customers. Chen maintained his Outperform rating on Sally Beauty shares.

TODAY'S FREE FLY STORIES

ENIA

Enel Americas

$9.25

-0.08 (-0.86%)

19:01
06/17/18
06/17
19:01
06/17/18
19:01
Upgrade
Enel Americas rating change  »

Enel Americas upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UL

Unilever; also tag UN

$54.26

0.64 (1.19%)

, UN

Unilever; also tag UL

$54.74

0.7 (1.30%)

18:55
06/17/18
06/17
18:55
06/17/18
18:55
Periodicals
Unilever taking stand against digital media's fake followers, Reuters says »

Unilever, the…

UL

Unilever; also tag UN

$54.26

0.64 (1.19%)

UN

Unilever; also tag UL

$54.74

0.7 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$98.91

(0.00%)

, CMCSA

Comcast

$33.85

0.03 (0.09%)

16:58
06/17/18
06/17
16:58
06/17/18
16:58
Hot Stocks
Box Office Battle: 'Incredibles 2' breaks record with $180M »

Disney (DIS) and…

TWX

Time Warner

$98.91

(0.00%)

CMCSA

Comcast

$33.85

0.03 (0.09%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$49.11

-0.02 (-0.04%)

FOX

21st Century Fox

$44.57

0.14 (0.32%)

FOXA

21st Century Fox

$44.60

0.03 (0.07%)

LGF.A

Lionsgate

$26.57

1.52 (6.07%)

DIS

Disney

$108.91

0.15 (0.14%)

VIAB

Viacom

$29.40

0.49 (1.69%)

VIA

Viacom

$33.95

0.15 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

, OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

16:46
06/17/18
06/17
16:46
06/17/18
16:46
Conference/Events
JPMorgan to hold a conference »

3rd Annual Energy Equity…

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

SRCE

1st Source

$55.36

0.13 (0.24%)

LGCY

Legacy Reserves

$6.07

-0.03 (-0.49%)

EVA

Enviva

$29.35

0.15 (0.51%)

CRC

California Resources

$35.03

-2.57 (-6.84%)

INSM

Insmed

$26.74

-1.5 (-5.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Sep

16:43
06/17/18
06/17
16:43
06/17/18
16:43
Conference/Events
Leerink to hold a tour »

Ribs N' Bones Bus…

16:40
06/17/18
06/17
16:40
06/17/18
16:40
Conference/Events
Citigroup to hold a conference »

2018 European Healthcare…

GM

General Motors

$43.91

0.32 (0.73%)

, FCAU

Fiat Chrysler

$20.86

-0.37 (-1.74%)

16:38
06/17/18
06/17
16:38
06/17/18
16:38
Periodicals
Automakers putting smaller engines into big trucks, WSJ reportsFord »

U.S. auto makers are…

GM

General Motors

$43.91

0.32 (0.73%)

FCAU

Fiat Chrysler

$20.86

-0.37 (-1.74%)

F

Ford

$11.88

-0.01 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

MSFT

Microsoft

$100.24

-1.14 (-1.12%)

, GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

16:34
06/17/18
06/17
16:34
06/17/18
16:34
Periodicals
Microsoft is fixing office, WSJ reports »

The new version of…

MSFT

Microsoft

$100.24

-1.14 (-1.12%)

GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Oct

16:34
06/17/18
06/17
16:34
06/17/18
16:34
Conference/Events
Deutsche Bank to hold a conference »

Taiwan Auto Electronics…

WFC

Wells Fargo

$54.99

0.23 (0.42%)

, MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

16:33
06/17/18
06/17
16:33
06/17/18
16:33
Conference/Events
Federal Reserve Bank of New York to hold a conference »

Reforming Culture &…

WFC

Wells Fargo

$54.99

0.23 (0.42%)

MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

BAC

Bank of America

$29.27

-0.24 (-0.81%)

C

Citi

$66.34

0.18 (0.27%)

WBK

Westpac Banking

$20.67

0.125 (0.61%)

GS

Goldman Sachs

$232.00

-1.695 (-0.73%)

BCS

Barclays

$10.59

-0.225 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 21

    Jun

  • 22

    Jun

  • 13

    Jul

  • 10

    Sep

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 16

    Jul

  • 15

    Oct

  • 15

    Oct

F

Ford

$11.88

-0.01 (-0.08%)

16:25
06/17/18
06/17
16:25
06/17/18
16:25
Hot Stocks
Ford acquires Michigan Central Station »

Ford Motor has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$54.81

1.165 (2.17%)

16:22
06/17/18
06/17
16:22
06/17/18
16:22
Hot Stocks
Bristol-Myers' ELOQUENT-3 trial meets primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 10

    Jul

PTCT

PTC Therapeutics

$37.57

-0.75 (-1.96%)

, RHHBY

Roche

$0.00

(0.00%)

16:18
06/17/18
06/17
16:18
06/17/18
16:18
Hot Stocks
PTC Therapeutics presents updated preliminary data from SMA FIREFISH Program »

PTC Therapeutics (PTCT)…

PTCT

PTC Therapeutics

$37.57

-0.75 (-1.96%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

16:15
06/17/18
06/17
16:15
06/17/18
16:15
Hot Stocks
Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PERY

Perry Ellis

$27.92

0.31 (1.12%)

16:12
06/17/18
06/17
16:12
06/17/18
16:12
Hot Stocks
Perry Ellis enters into $437M transaction to become private company »

Perry Ellis International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSTM

Verastem

$6.53

0.95 (17.03%)

16:08
06/17/18
06/17
16:08
06/17/18
16:08
Hot Stocks
Verastem presents duvelisib data at EHA 2018 annual meeting »

Verastem announced one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

IQ

iQIYI

$40.16

-0.44 (-1.08%)

16:05
06/17/18
06/17
16:05
06/17/18
16:05
Hot Stocks
iQIYI obtains broadcasting rights for all four golf majors »

iQIYI announced it had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$200.55

0.86 (0.43%)

15:56
06/17/18
06/17
15:56
06/17/18
15:56
Conference/Events
Home Depot participates in a field trip with UBS »

Field Trip to Atlanta, GA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAY

Verifone

$22.84

0.01 (0.04%)

15:28
06/17/18
06/17
15:28
06/17/18
15:28
Conference/Events
Verifone to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACI

CACI

$167.60

1.1 (0.66%)

14:18
06/17/18
06/17
14:18
06/17/18
14:18
Conference/Events
CACI to hold a webcast »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

ARGX

Argenx

$92.38

-3.32 (-3.47%)

14:11
06/17/18
06/17
14:11
06/17/18
14:11
Conference/Events
Argenx to hold a KOL breakfast symposium »

Management holds a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PTC

PTC

$94.87

-0.46 (-0.48%)

14:06
06/17/18
06/17
14:06
06/17/18
14:06
Conference/Events
PTC to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:41
06/17/18
06/17
13:41
06/17/18
13:41
Conference/Events
Federal Reserve Bank of Atlanta president speaks at a meeting »

Atlanta Federal Reserve…

VRX

Valeant

$26.86

0.06 (0.22%)

13:31
06/17/18
06/17
13:31
06/17/18
13:31
Conference/Events
Breaking Conference/Events news story on Valeant »

FDA PDUFA Date for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 27

    Aug

WMGI

Wright Medical

$25.83

-0.26 (-1.00%)

13:27
06/17/18
06/17
13:27
06/17/18
13:27
Conference/Events
Wright Medical management to meet with Leerink »

Meeting to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.